Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded at StockNews.com

StockNews.com upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a hold rating to a buy rating in a research report report published on Saturday morning.

A number of other analysts also recently weighed in on the stock. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an overweight rating on the stock in a research report on Thursday, August 8th. Needham & Company LLC reaffirmed a hold rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $63.00.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH stock opened at $46.79 on Friday. The business’s fifty day moving average is $40.70 and its 200 day moving average is $43.45. The company has a quick ratio of 1.72, a current ratio of 2.18 and a debt-to-equity ratio of 0.88. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 0.75 and a beta of 0.79. Amphastar Pharmaceuticals has a twelve month low of $36.56 and a twelve month high of $65.92.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 17,101 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the sale, the director now directly owns 33,971 shares in the company, valued at approximately $1,463,130.97. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Richard K. Prins sold 17,101 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the transaction, the director now directly owns 33,971 shares of the company’s stock, valued at approximately $1,463,130.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, June 10th. The stock was sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the sale, the director now directly owns 78,409 shares of the company’s stock, valued at approximately $3,246,132.60. The disclosure for this sale can be found here. Insiders sold a total of 34,479 shares of company stock valued at $1,484,022 in the last quarter. 27.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of AMPH. YHB Investment Advisors Inc. purchased a new position in shares of Amphastar Pharmaceuticals during the first quarter valued at approximately $27,000. Principal Securities Inc. purchased a new stake in Amphastar Pharmaceuticals during the 4th quarter valued at $34,000. Innealta Capital LLC bought a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at $55,000. Quadrant Capital Group LLC grew its holdings in shares of Amphastar Pharmaceuticals by 27.8% in the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after acquiring an additional 223 shares during the period. Finally, Blue Trust Inc. increased its position in Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.